Aeroplysinin-1, a Sponge-Derived Multi-Targeted Bioactive Marine Drug

Marine Drugs

Volumn 14, Issue 1, 2016, Pages

  García Vilas, Javier A ^a,b   Martínez Poveda, Beatriz ^a,c   Quesada, Ana R ^a,b   Medina, Miguel Ángel ^a,b  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

(+) aeroplysinin 1; Angiogenesis; Cancer; Inflammation; Marine drugs; Sponges

Indexed keywords

AEROPLYSININ 1; ALKALOID DERIVATIVE; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; ACETONITRILE DERIVATIVE; AEROPLYSININ I; ANTIINFECTIVE AGENT; CYCLOHEXENE DERIVATIVE; SEA WATER;

ANTIANGIOGENIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; CONCENTRATION RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; NONHUMAN; REVIEW; SPONGE (PORIFERA); VERONGIDA; ANIMAL; CHEMISTRY; DRUG EFFECTS; GRAM POSITIVE BACTERIUM;

ACETONITRILES; ANIMALS; ANTI-BACTERIAL AGENTS; CYCLOHEXENES; GRAM-POSITIVE BACTERIA; HUMANS; PORIFERA; SEAWATER;

EID: 84961345478     PISSN: None     EISSN: 16603397     Source Type: Journal    
DOI: 10.3390/md14010001     Document Type: Review

References (59)

1. Paul, V.J. Activation of chemical defenses in the tropical green algae Halimeda spp. J. Exp. Mar. Biol. Ecol. 1992, 160, 191-203. [CrossRef]
2. Engel, S.; Jensen, P.R.; Fenical, W. Chemical ecology of marine microbial defense. J. Chem. Ecol. 2002, 28, 1971-1985. [CrossRef] [PubMed]
3. Walters, K.D.; Pawlik, J.R. Is there a trade-off between wound-healing and chemical defenses among Caribbean reef sponges? Integr. Comp. Biol. 2005, 45, 352-358. [CrossRef] [PubMed]
4. Green, G. Ecology of toxicity in marine sponges. Mar. Biol. 1977, 40, 207-215. [CrossRef]
5. Koopmans, M.; Martens, D.; Wijffels, R.H. Towards commercial production of sponge medicines. Mar. Drugs 2009, 7, 787-802. [CrossRef] [PubMed]
6. Unson, M.D.; Holland, N.D.; Faulkner, D.J. A brominated secondary metabolite synthesized by the cyanobacterial symbiont of a marine sponge and accumulation of the crystalline metabolite in the sponge tissue. Mar. Biol. 1994, 119, 1-11. [CrossRef]
7. Thoms, C.; Ebel, R.; Proksch, P. Activated chemical defense in Aplysina sponges revisited. J. Chem. Ecol. 2006, 32, 97-123. [CrossRef] [PubMed]
8. Li, J.W.; Vederas, J.C. Drug discovery and natural products: End of an era or an endless frontier? Science 2009, 325, 161-165. [CrossRef] [PubMed]
9. Harvey, A.L.; Clark, R.L.; Mackay, S.P.; Johnston, B.F. Current strategies for drug discovery through natural products. Exp. Opin. Drug Dis. 2010, 5, 559-568. [CrossRef] [PubMed]
10. Wohlleben, W.; Pelzer, S. New compounds by combining "Modern" genomics and "Old-Fashioned" mutasynthesis. Chem. Biol. 2002, 9, 1163-1164. [CrossRef]
11. Datta, D.; Nath Talapatra, S.; Swarnakar, S. Bioactive compounds from marine invertebrates for potential medicines-An overview. Int. Lett. Nat. Sci. 2015, 7, 42-61. [CrossRef]
12. Laport, M.S.; Santos, O.C.S.; Muricy, G. Marine sponges: Potential sources of new antimicrobial drugs. Curr. Pharm. Biotechnol. 2009, 10, 86-105. [CrossRef] [PubMed]
13. Kunze, K.; Niemann, H.; Ueberlein, S.; Schulze, R.; Ehrlich, H.; Brunner, E.; Proksch, P.; Van Pée, K.H. Brominated skeletal components of the marine demosponges, Aplysina cavernicola and Ianthella basta: Analytical and biochemical investigations. Mar. Drugs 2013, 11, 1271-1287. [CrossRef] [PubMed]
14. Diaz, M.C.; Thacker, R.W.; Redmond, N.E.; Matterson, K.O.; Collins, A.G. Phylogenetic novelties and geographic anomalies among tropical verongida. Integr. Comp. Biol. 2013, 53, 482-494. [CrossRef] [PubMed]
15. Erwin, P.M.; Thacker, R.W. Phylogenetic analyses of marine sponges within the order Verongida: A comparison of morphological and molecular data. Invertebr. Biol. 2007, 126, 220-234. [CrossRef]
16. Ivanova, E.P.; Kuznetsova, T.A.; Mikhailov, V.V. Antifungal compounds produced by bacterial populations of the Sea Sponge Verongia sp. Russ. J. Mar. Biol. 2000, 26, 118-119. [CrossRef]
17. Muscholl-Silberhorn, A.; Thiel, V.; Imhoff, J.F. Abundance and bioactivity of cultured sponge-associated bacteria from the Mediterranean Sea. Microb. Ecol. 2008, 55, 94-106. [CrossRef] [PubMed]
18. Gerçe, B.; Schwartz, T.; Voigt, M.; Rühle, S.; Kirchen, S.; Putz, A.; Proksch, P.; Obst, U.; Syldatk, C.; Husamann, R. Morphological, bacterial, and secondary metabolite changes of Aplysina aerophoba upon long-term maintenance under artificial conditions. Microb. Ecol. 2009, 58, 865-878. [CrossRef] [PubMed]
19. Turon, X.; Becerro, M.; Uriz, M.J. Distribution of brominated compounds within the sponge Aplysina aerophoba: Coupling of X-ray microanalysis with cryofixation techniques. Cell Tissue Res. 2000, 301, 311-322. [CrossRef] [PubMed]
20. Friedrich, A. Temporal variation of the microbial community associated with the mediterranean sponge Aplysina aerophoba. FEMS Microbiol. Ecol. 2001, 38, 105-113. [CrossRef]
21. Ciminiello, P.; Fattorusso, E.; Forino, M.; Magno, S.; Pansini, M. Chemistry of verongida sponges VIII-Bromocompounds from mediterranean sponges Aplysina aerophoba and Aplysina cavernicola. Tetrahedron 1997, 53, 6565-6572. [CrossRef]
22. Kochanowska, A.J.; Rao, K.V.; Childress, S.; El-Alfy, A.; Matsumoto, R.R.; Kelly, M.; Stewart, G.S.; Sufka, K.J.; Hamann, M.T. Secondary metabolites from three Florida sponges with antidepressant activity. J. Nat. Prod. 2008, 71, 186-189. [CrossRef] [PubMed]
23. Sacristán-Soriano, O.; Banaigs, B.; Becerro, M.A. Temporal trends in the secondary metabolite production of the sponge Aplysina aerophoba. Mar. Drugs 2012, 10, 677-693. [CrossRef] [PubMed]
24. Ebel, R.; Brenzinger, M.; Kunze, A.; Gross, H.J.; Proksch, P.Wound activation of protoxins in marine sponge Aplysina aerophoba. J. Chem. Ecol. 1997, 23, 1451-1462. [CrossRef]
25. Lira, N.S.; Carneiro-Montes, R.; Fechine-Tavares, J.; Sobral da Silva, M.; da Cunha, E.; Filgueiras, P.; Rodrigues, L.C.; da Silva Dias, C.; Barbosa-Fiho, J.M. Brominated compounds from marine sponges of the genus Aplysina and a compilation of their 13C NMR spectral data. Mar. Drugs 2011, 9, 2316-2368. [CrossRef] [PubMed]
26. Teeyapant, R.; Proksch, P. Biotransformation of brominated compounds in the marine sponge Verongia aerophoba-Evidence for an induced chemical defense? Naturwissenschaften 1993, 80, 369-370. [CrossRef]
27. Lipowicz, B.; Hanekop, N.; Schmitt, L.; Proksch, P. An aeroplysinin-1 specific nitrile hydratase isolated from the marine sponge Aplysina cavernicola. Mar. Drugs 2013, 11, 3046-3067. [CrossRef] [PubMed]
28. Fulmor, W.; Van Lear, G.E.; Morton, G.O.; Mills, R.D. Isolation and absolute configuration of the aeroplysinin I enantiomorphic pais from Ianthella ardis. Tetrahedron. Lett. 1970, 52, 4551-4552. [CrossRef]
29. Fattorusso, E.; Minale, L.S.G. Aeroplysinin-1, an antibacterial bromo-compound from the sponge Verongia aerophoba. J. Chem. Soc. 1972, 1, 16-18. [CrossRef]
30. Andersen, R.J.; Faulkner, D.J. Synthesis of aeroplysinin-1 and related compounds. J. Am. Chem. Soc. 1975, 97, 936-937. [CrossRef]
31. Nieto-Ortega, B.; Casado, J.; Blanck, E.W.; López-Navarrete, J.; Quesada, A.R.; Ramírez, F.J. Raman optical activity spectra and conformational elucidation of chiral drugs. The case of the antiangiogenic aeroplysinin-1. J. Phys. Chem. A 2011, 115, 2752-2755. [CrossRef] [PubMed]
32. Weiss, B.; Ebel, R.; Elbrächter, M.; Kirchner, M.; Proksch, P. Defense metabolites from the marine sponge Verongia aerophoba. Biochem. Syst. Ecol. 1996, 24, 1-12. [CrossRef]
33. Teeyapant, R.;Woerdenbag, H.J.; Kreis, P.; Hacker, J.;Wray, V.;Witte, L.; Proksch, P. Antibiotic and cytotoxic activity of brominated compounds from the marine sponge Verongia aerophoba. Z. Naturforsch. C 1993, 48, 939-945. [PubMed]
34. Gómez-Archila, L.; Zapata, W.; Galeano, E.; Martínez, A.; Díaz, F.J.; Rugeles, M.T. Bromotyrosine derivatives from marine sponges inhibit the HIV-1 replication in vitro. VITAE. Rev. Fac. Química Farm. 2014, 21, 114-125.
35. Aderem, A.; Ulevitch, R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406, 782-787. [CrossRef] [PubMed]
36. Fulkerson, P.C.; Rothenberg, M.E. Targeting eosinophils in allergy, inflammation and beyond. Nat. Rev. Drug Discov. 2013, 12, 117-129. [CrossRef] [PubMed]
37. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674. [CrossRef] [PubMed]
38. Martínez-Poveda, B.; García-Vilas, J.A.; Cárdenas, C.; Melgarejo, E.; Quesada, A.R.; Medina, M.A. The brominated compound aeroplysinin-1 inhibits proliferation and the expression of key pro-inflammatory molecules in human endothelial and monocyte cells. PLoS ONE 2013, 8, e55203. [CrossRef] [PubMed]
39. Martínez-Poveda, B.; Rodríguez-Nieto, S.; García-Caballero, M.; Medina, M.A.; Quesada, A.R. The antiangiogenic compound aeroplysinin-1 induces apoptosis in endothelial cells by activating the mitochondrial pathway. Mar. Drugs 2012, 10, 2033-2046. [CrossRef] [PubMed]
40. Rodríguez-Nieto, S.; González-Iriarte, M.; Carmona, R.; Muñoz-Chápuli, R.; Medina, M.A.; Quesada, A.R. Antiangiogenic activity of aeroplysinin-1, a brominated compound isolated from a marine sponge. FASEB J. 2001, 16. [CrossRef]
41. Rodríguez-Caso, L.; Reyes-Palomares, A.; Sánchez-Jiménez, F.; Quesada, A.R.; Medina, M.A. What is knwon on angiogenesis-related rare diseases? A systematic review of literature. J. Cell. Mol. Med. 2012, 16, 2872-2893. [CrossRef] [PubMed]
42. Córdoba, R.; Salvaro-Tormo, N.; Fernñandez-Medarde, A.; Plumet, J. Angiogenic versus cytotoxic activity in analogues of aeroplysinin-1. Bioorg. Med. Chem. 2007, 15, 5300-5315. [CrossRef] [PubMed]
43. Kreuter, M.H.; Bernd, A.; Holzmann, H.; Müller.Klieser, W.; Maidhof, A.; Weissmann, N.; Kljajic, Z.; Batel, R.; Schröder, H.C.; Müller, W.E.G. Cytostatic activity of aeroplysinin-1 against lymphoma and epithelioma cells. Z. Naturforsch. C 1989, 44, 680-688. [PubMed]
44. Kreuter, M.H.; Leake, R.E.; Rinaldi, F.; Müller-Klieser, W.; Maidhof, A.; Müller, W.E.; Schröder, H.C. Inhibition of intrinsic protein tyrosine kinase activity of EGF-receptor kinase complex from human breast cancer cells by the marine sponge metabolite (+)-aeroplysinin-1. Comp. Biochem. Physiol. B 1990, 97, 151-158. [CrossRef]
45. Stuhldreier, F.; Kassel, S.; Schumacher, L.; Wesselborg, S.; Proksch, P.; Fritz, G. Pleiotropic effects of spongean alkaloids on mechanisms of cell death, cell cycle progression and DNA damage response (DDR) of acute myeloid leukemia (AML) cells. Cancer Lett. 2015, 361, 39-48. [CrossRef] [PubMed]
46. Takeuchi, K.; Ito, F. Target Therapy for Cancer: Anti-cancer drugs targeting growth-factor signaling molecules receptor tyrosine kinases and targeted cancer therapeutics. Biopharm. Bull. 2011, 34, 1774-1780. [CrossRef]
47. Hinterding, K.; Knebel, A.; Herrlich, P.; Waldmann, H. Synthesis and biological evaluation of aeroplysinin analogues: A new class of receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. 1998, 6, 1153-1162. [CrossRef]
48. Koulman, A.; Proksch, P.; Rainer, E.; Beekman, A.C.; Van Uden, W.; Konings, A.W.T.; Pedersen, J.A.; Pras, N.; Woerdenbag, J. Cytotoxicity and mode of action aeroplysinin-1 and a related dienone from the sponge Aplysina aerophoba. J. Nat. Prod. 1996, 59, 591-594. [CrossRef] [PubMed]
49. Perovíc-Ottstadt, S.; Adell, T.; Proksch, P.;Wiens, M.; Korzhev, M.; Gamulin, V.; Müller, I.M.; Müller,W.E.G. A (1Ñ3)---D-glucan recognition protein from the sponge Suberites domuncula. Mediated activation of fibrinogen-like protein and epidermal growth factor gene expression. Eur. J. Biochem. 2004, 271, 1924-1937.
50. (+-Aeroplysinin-1 (CAS 28656-91-9). Available online: Http://www.scbt.com/es/datasheet-202445-aeroplysinin-1.html (accessed on 11 October 2015).
51. Martínez-Poveda, B.; Quesada, A.R.; Medina, M.A. (+)-Aeroplysinin-1 inhibits Akt and ERK pathway signaling selectively in endothelial cells. Integr. Cancer Sci. Ther. 2015, 2, 181-184.
52. Muñoz-Chápuli, R.; Quesada, A.R.; Medina, M.A. Angiogenesis and signal transduction in endothelial cells. Cell. Mol. Life Sci. 2004, 61, 2224-2243. [CrossRef] [PubMed]
53. García-Godoy, M.J.; López-Camacho, E.; García-Nieto, J.; Aldana-Montes, A.J. Solving molecular docking problems with multi-objective metaheuristics. Molecules 2015, 20, 10124-10183. [CrossRef] [PubMed]
54. Bhatnagar, I.; Kim, S.K. Immense essence of excellence: Marine microbial bioactive compounds. Mar. Drugs 2010, 8, 2673-2701. [CrossRef] [PubMed]
55. Imhoff, J.F.; Labes, A.; Wiese, J. Bio-mining the microbial treasures of the ocean: New natural products. Biotechnol. Adv. 2011, 29, 468-482. [CrossRef] [PubMed]
56. Castro, M.E.; González-Iriarte, M.; Barrero, A.F.; Salvador-Tormo, N.; Muñoz-Chápuli, R.; Medina, M.A.; Quesada, A.R. Study of puupehenone and related compounds as inhibitors of angiogenesis. Int. J. Cancer 2004, 110, 31-38. [CrossRef] [PubMed]
57. Martínez-Poveda, B.; Quesada, A.R.; Medina, M.A. The anti-angiogenic 8-epipuupehedione behaves as a potential anti-leukemic compound against HL-60 cells. J. Cell. Mol. Med. 2008, 12, 701-706. [CrossRef] [PubMed]
58. García-Caballero, M.; Marí-Beffa, M.; Cañedo, L.; Medina, M.A.; Quesada, A.R. Toluquinol, a marine fungus metabolite, is a new angiosuppresor that interferes the Akt pathway. Biochem. Pharmacol. 2013, 85, 1727-1740. [CrossRef] [PubMed]
59. García-Caballero, M.; Cañedo, L.; Fernández-Medarde, A.; Medina, M.A.; Quesada, A.R. The marine fungal metabolite, AD0157, inhibits angiogenesis by targeting the Akt signaling pathway. Mar. Drugs 2014, 12, 279-299. [CrossRef] [PubMed]